Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2D | O15399 | 1/20 | 0.31 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.31 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.31 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.31 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.31 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.31 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | GMNN | O75496 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.30 |
| ▸ | MMP2 | P08253 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | MMP9 | P14780 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7051387 | 0.79 | SMN1; SMN2 (0.36) | HSD11B1LMNATP53CYP2D6TSHR | |
| SCHEMBL28094317 | 0.78 | HSD11B1 (0.33) | HSD11B1 | |
| SCHEMBL6217800 | 0.78 | CYP1A2 (0.33) | HSD11B1LMNA | |
| SCHEMBL3516279 | 0.78 | MYC (0.30) | — | |
| SCHEMBL25712668 | 0.78 | CYP1A2 (0.30) | CYP2D6TSHR | |
| SCHEMBL525836 | 0.76 | — | — | |
| SCHEMBL28094116 | 0.75 | HSD11B1 (0.33) | HSD11B1KDM4ELMNAMAPTHTT | |
| SCHEMBL1836164 | 0.75 | PARP1 (0.36) | KDM4ELMNATP53MAPTTSHR | |
| SCHEMBL29106412 | 0.75 | SMN1; SMN2 (0.33) | LMNATP53MAPTSMN1; SMN2 | |
| SCHEMBL30511570 | 0.75 | PARP1 (0.36) | KDM4ELMNATP53MAPTTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-5310737-A | — | — | None | — | — | JP | disclosed |
| US-20240343710-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | 1CBIO, INC. | 2024-10-17 | — | — | US | disclosed |
| US-20240101531-A1 | PYRIDINAMINE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | XENON PHARMACEUTICALS INC. (CA) | 2024-03-28 | — | — | US | disclosed |
| CN-116710453-A | Kinase inhibitors and uses thereof | 璧辰医药技术股份有限公司 | 2023-09-05 | — | — | CN | disclosed |
| CN-109476672-A | NOVEL HETEROCYCLIC DERIVATIVE COMPOUND AND USE THEREOF | 韩美药品株式会社 | 2019-03-15 | — | — | CN | disclosed |
| EP-3302479-A1 | TUMOR BIOMARKERS AND USE THEREOF | Curegenix Corporation (US) | 2018-04-11 | — | — | EP | disclosed |
| US-20170267673-A1 | CYCLOPROPYL FUSED THIAZIN-2-AMINE COMPOUNDS AS BETA-SECRETASE INHIBITORS AND METHODS OF USE | AMGEN INC. (US) | 2017-09-21 | — | — | US | disclosed |
| US-9556135-B2 | Amino-dihydrothiazine and amino-dioxido dihydrothiazine compounds as beta-secretase antagonists and methods of use | AMGEN, INC. (US) | 2017-01-31 | — | — | US | disclosed |
| US-9550762-B2 | Cyclopropyl fused thiazin-2-amine compounds as beta-secretase inhibitors and methods of use | AMGEN, INC. (US) | 2017-01-24 | — | — | US | disclosed |
| WO-2016191525-A1 | TUMOR BIOMARKERS AND USE THEREOF | CUREGENIX CORPORATION (US) | 2016-12-01 | — | — | WO | disclosed |
| US-4604401-A | QUINOLINE-CARBOXYLIC ACIDS | WARNER-LAMBERT COMPANY (US) | 1986-08-05 | — | — | US | disclosed |
| EP-0169710-A2 | 7-Substituted-6-fluoro-8-substituted-1,4-dihydro-1-methylamino-4-oxo-3-quinolinecarboxylic acids; 7-substituted-6-fluoro-1,4-dihydro-1-methylamino-4-oxo-3-naphthyridine carboxylic acids; derivatives thereof; and processes for producing the compounds | WARNER-LAMBERT COMPANY (US) | 1986-01-29 | — | — | EP | disclosed |
| US-4517191-A | 1-Amino-1,8-naphthyridine compounds useful as bactericides | STERLING DRUG INC. (US) | 1985-05-14 | — | — | US | disclosed |
| US-4260759-A | CONDENSATION OF NITRILES | SCHERING-CORPORATION (US) | 1981-04-07 | — | — | US | disclosed |
| US-4260759-A | CONDENSATION OF NITRILES | SCHERING-CORPORATION (US) | 1981-04-07 | — | — | US | disclosed |
| US-4115395-A | FUNGICIDES, BACTERICIDES | SCHERING CORPORATION (US) | 1978-09-19 | — | — | US | disclosed |
| US-4115395-A | FUNGICIDES, BACTERICIDES | SCHERING CORPORATION (US) | 1978-09-19 | — | — | US | disclosed |
| US-4107166-A | ANTIFUNGAL, ANTIBACTERIAL | SCHERING CORPORATION (US) | 1978-08-15 | — | — | US | disclosed |
| US-4017500-A | FUNGICIDES, BACTERICIDES | SCHERING CORPORATION (US) | 1977-04-12 | — | — | US | disclosed |
| US-3928367-A | 1-Amino naphthyridines | SCHERING CORP | 1975-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240101531-A1 | PYRIDINAMINE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | KCNA1, KCNB1, KCNB2 | GRIN2D 203/4885GRIN3B 297/4885GRIN1 137/4885 |
| US-20240343710-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | PARP1, PARP11, PARP12 | GRIN2D 3388/4885GRIN3B 2207/4885GRIN1 2653/4885 |
| US-20170267673-A1 | CYCLOPROPYL FUSED THIAZIN-2-AMINE COMPOUNDS AS BETA-SECRETASE INHIBITORS AND METHODS OF USE | BACE1, BACE2, APP | GRIN2D 726/4885GRIN3B 343/4885GRIN1 480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.